Scopus BioPharma Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Greenspan Ira Scott, was filed 30 Aug 2021.
Scopus BioPharma Inc.: what insiders have been doing
This page follows insider dealings at Scopus BioPharma Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Scopus BioPharma Inc. has had no insider filing for more than a year; the last one goes back to 17 November 2021.
Looking back to 2021, when coverage begins, insiders filed 31 purchases and no sales.
Other companies in the same sector with recent insider buying flagged by our signals: Xenon Pharmaceuticals Inc. and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Since the insiders bought
- -93.7%Entry US$5.49 · Close at T+365 US$0.35
- -92.7%Entry US$5.08 · Close at T+365 US$0.37
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
- 6,333 sharesCommon StockSEC:0000895813-21-000017:1
- 700,000 sharesCommon StockSEC:0000895813-21-000017:0
- 790 shares@ US$4.98Common Stock, par value $0.001SEC:0001104659-21-110764:1Canonical exit: 25 Nov 2021 (T+90)
- 110 shares@ US$4.922.7% of flowCommon Stock, par value $0.001SEC:0001104659-21-110764:0Canonical exit: 25 Nov 2021 (T+90)
- 200 shares@ US$5.00Common Stock, par value $0.001SEC:0001104659-21-110652:1Canonical exit: 25 Nov 2021 (T+90)
- 200 shares@ US$4.908.7% of flowCommon Stock, par value $0.001SEC:0001104659-21-110652:0Canonical exit: 24 Nov 2021 (T+90)
- 50 shares@ US$4.65Common Stock, par value $0.001SEC:0001104659-21-109182:1Canonical exit: 22 Nov 2021 (T+90)
- 500 shares@ US$4.4110.9% of flowCommon Stock, par value $0.001SEC:0001104659-21-109182:0Canonical exit: 21 Nov 2021 (T+90)
- 400 shares@ US$4.23Common Stock, par value $0.001SEC:0001104659-21-108376:1Canonical exit: 18 Nov 2021 (T+90)
- 800 shares@ US$4.0428.8% of flowCommon Stock, par value $0.001SEC:0001104659-21-108657:0Canonical exit: 17 Nov 2021 (T+90)
- 2,000 shares@ US$4.0440.1% of flowCommon Stock, par value $0.001SEC:0001104659-21-108376:0Canonical exit: 17 Nov 2021 (T+90)
- 1,000 shares@ US$4.27Common Stock, par value $0.001SEC:0001104659-21-107826:1Canonical exit: 16 Nov 2021 (T+90)
- 1,000 shares@ US$4.1320.5% of flowCommon Stock, par value $0.001SEC:0001104659-21-107826:0Canonical exit: 15 Nov 2021 (T+90)
- 1,000 shares@ US$4.78Common Stock, par value $0.001SEC:0001104659-21-096344:1Canonical exit: 24 Oct 2021 (T+90)
- 400 shares@ US$4.76Common Stock, par value $0.001SEC:0001104659-21-096344:2Canonical exit: 24 Oct 2021 (T+90)
- 200 shares@ US$4.54Common Stock, par value $0.001SEC:0001104659-21-096344:3Canonical exit: 25 Oct 2021 (T+90)
- 1,500 shares@ US$4.7162.5% of flowCommon Stock, par value $0.001SEC:0001104659-21-096342:0Canonical exit: 21 Oct 2021 (T+90)
- 1,100 shares@ US$4.7725.8% of flowCommon Stock, par value $0.001SEC:0001104659-21-096344:0Canonical exit: 21 Oct 2021 (T+90)
- 150 shares@ US$9.46Common Stock, par value $0.001SEC:0001104659-21-028944:0Canonical exit: 25 May 2021 (T+90)
- 150 shares@ US$9.29Common Stock, par value $0.001SEC:0001104659-21-028944:1Canonical exit: 26 May 2021 (T+90)
- 115 shares@ US$9.48Common Stock, par value $0.001SEC:0001104659-21-028948:0Canonical exit: 25 May 2021 (T+90)
- 300 shares@ US$9.45Common Stock, par value $0.001SEC:0001104659-21-028948:1Canonical exit: 25 May 2021 (T+90)
- 800 shares@ US$9.01Common Stock, par value $0.001SEC:0001104659-21-028948:2Canonical exit: 26 May 2021 (T+90)
- 200 shares@ US$9.58Common Stock, par value $0.001SEC:0001104659-21-027147:0Canonical exit: 24 May 2021 (T+90)
- 1,300 shares@ US$9.66Common Stock, par value $0.001SEC:0001104659-21-027147:1Canonical exit: 24 May 2021 (T+90)
25 of 33 declarations
About Scopus BioPharma Inc.
Scopus BioPharma Inc. (ticker: SCPS) is a U.S.-listed biopharmaceutical company traded on NASDAQ in the United States, focused on developing innovative therapies for serious diseases with significant unmet medical needs. The company was incorporated in Delaware in 2017 under the name Project18 Inc. and changed its name to Scopus BioPharma later that year. Its principal executive offices have been identified in New York, with additional operational ties to Israel and, historically, research-related activities associated with Los Angeles. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1772028/000110465920085668/tm2024664d1_partiiandiii.htm?utm_source=openai))
Scopus BioPharma describes itself as an early-stage biotech built around collaboration with leading academic and research institutions. Its publicly described strategic partners have included City of Hope, the NIH, and Hebrew University, reflecting a model that depends on external scientific discovery, translational research, and licensing or partnership structures rather than a fully integrated commercial platform. For equity investors, this makes SCPS a development-stage story where valuation is driven primarily by pipeline progress, intellectual-property strength, and financing capacity. ([scopusbiopharma.com](https://scopusbiopharma.com/about/overview/?utm_source=openai))
Read moreShow less
In terms of business lines, the company has been centered on oncology and immunotherapy programs. Historical SEC and company materials highlight a lead candidate built around STAT3 targeting, a pathway widely associated with cell growth, immune response, and cancer biology, as well as additional immunotherapy-oriented assets. Scopus also announced the acquisition of Olimmune as part of an effort to expand its immunotherapy pipeline. This suggests a narrow but science-intensive portfolio with potential upside if clinical translation and partnering succeed, but also substantial clinical, regulatory, and funding risk. ([scopusbiopharma.com](https://scopusbiopharma.com/wp-content/uploads/Scopus-BioPharma-Expands-Immunotherapy-Pipeline-with-Acquisition-of-Olimmune-06.30.21-FINAL.pdf?utm_source=openai))
From a competitive standpoint, Scopus BioPharma is a small-cap biotech competing in a crowded field against larger pharmaceutical companies and better-capitalized specialty biotechs. Its differentiation lies in targeting biologically complex mechanisms and in its academic-network approach, but it does not have the scale, diversification, or commercial revenue base of established pharma peers. Public filings describe the company as early-stage and note that it had not generated revenues, which reinforces the speculative nature of the investment case. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1772028/000141057823000666/scps-20221231x10k.htm?utm_source=openai))
Geographically, the company’s footprint is primarily U.S.-based, with headquarters in New York and a corporate setup that includes Israeli exposure through subsidiary or collaboration infrastructure. Recent public materials available online emphasize recapitalization, pipeline reshaping, and strategic asset integration more than late-stage commercialization. For investors tracking SEC Form 4 insider transactions, the key takeaway is that Scopus BioPharma remains a high-volatility development story in which insider activity, financing events, and pipeline updates can be particularly important market signals. ([scopusbiopharma.com](https://scopusbiopharma.com/wp-content/uploads/Scopus-BioPharma-Completes-Recapitalization-Designed-to-Enhance-Shareholder-Value-10.18.22-FINAL.pdf?utm_source=openai))
